Start with the question being asked

Semax is a synthetic seven-amino-acid peptide based on part of adrenocorticotropic hormone, or ACTH. Researchers have studied it in stroke recovery, other neurological conditions and healthy volunteers. Those are different questions: recovering function after injury and improving concentration in someone without that injury need their own evidence.[9][10]

In Russia, Semax has been registered as 0.1% and 1% nasal drops. The 1% instructions concern acute moderate or severe ischemic stroke as part of combined treatment. The 0.1% instructions list other uses, including recovery after stroke and certain cognitive disorders. Neither product label establishes that an online injection or modified peptide is equivalent.[9][10][11]

What the stroke studies actually measured

A 1997 study compared 30 patients receiving Semax alongside intensive stroke care with 80 patients receiving conventional treatment. It reported faster improvement in neurological symptoms, particularly movement. The accessible abstract describes matching for severity and location of stroke, but does not establish random allocation or blinding. It is a positive comparative signal with limited protection against bias.[4]

A 2018 Russian study followed 110 people undergoing rehabilitation after ischemic stroke. Participants were grouped by earlier or later rehabilitation, then randomized within those groups to receive nasal Semax or no Semax alongside rehabilitation. The paper reports better recovery on the Barthel scale, which measures activities such as dressing, walking and self-care, and higher blood BDNF, a protein involved in nerve-cell signalling.[2]

The findings were not equally strong for every outcome. The paper reported no significant Semax-related difference in the reduction of limb weakness. Earlier rehabilitation mattered for motor recovery. It described no placebo or blinding, and time since stroke differed between the two later-rehabilitation subgroups. A rise in blood BDNF also does not prove that new brain tissue formed or that BDNF caused the functional improvement.[2]

These results support further investigation of a possible adjunct to rehabilitation. They do not establish Semax as a replacement for emergency stroke treatment, prevention of another stroke or a structured rehabilitation programme.

Has it been tested in healthy people?

Yes. In a 1996 paper, 16 male power-plant operators were randomly assigned, under double-blind conditions, to nasal Semax or saline placebo. The Semax group performed better on several attention and short-term-memory task measures over two working days. There was also an unexplained increase in spontaneous false responses on one measure. Eight people per group and a brief workplace experiment are not enough to establish a dependable everyday cognitive benefit.[6]

A 2018 experiment involved 24 healthy adults, 14 receiving nasal Semax and 10 placebo. It found changes in a resting brain network measured by functional MRI. It did not demonstrate improved work performance, memory in daily life or prevention of dementia. The task study and the scan study should not be treated as the same kind of evidence.[7]

Other conditions have different results

A small open-label study in 27 people with motor neuron disease reported improved emotional and motivational aspects of quality of life. It did not show an effect on disease progression or pronounced functional deficits. A favourable experience in one part of life does not necessarily mean the underlying disease has slowed.[8]

Animal research continues. A 2025 mouse study reported improvements in behavioural tests and fewer amyloid deposits with Semax and a related peptide in an Alzheimer disease model. Rat stroke experiments have also found changes in immune, vascular and neuronal gene activity. These are useful research findings, but they do not establish treatment benefit in people with Alzheimer disease.[1][3][5]

Safety needs its own evidence

The 2018 rehabilitation paper reported no adverse effects or worsening of general medical condition, and 95% rated tolerability good or very good. That is reassuring within that study, while leaving rare reactions and prolonged use unresolved.[2]

The Russian nasal-product instructions list mild nasal irritation with prolonged use. They also list contraindications including pregnancy, breastfeeding, a history of seizures, acute psychiatric conditions and anxiety disorders. Age restrictions differ between the 0.1% and 1% products. These details matter when Semax is promoted broadly for mood or focus.[9][10]

FDA's July 2026 evaluation described one consumer report of eye pain and burning after online-purchased 0.1% nasal drops, with hospitalization and persistent pain reported. A report cannot establish that Semax caused the problem or estimate its frequency. It does show why an absence of published trial warnings is not proof of an absence of harm. FDA also identified missing safety data for subcutaneous use and potential immune-reaction concerns related to aggregation and impurities.[11]

A September 2026 preprint examining clinical notes about Semax and Selank recorded both patient-perceived benefits and safety concerns. Many people used several peptides, and the study could not determine effectiveness or causation. Its observations should not be read as either a treatment success rate or an adverse-event rate for Semax alone.[14]

Russian use and US policy are separate questions

Semax is not FDA-approved. FDA staff concluded in July 2026 that the evidence was insufficient for the proposed uses in cerebral ischemia, migraine and trigeminal neuralgia. Their evaluation excluded several Russian-language stroke papers because complete verified English translations were unavailable. That limitation matters when interpreting the review; those studies still exist and need appraisal on their own merits.[11]

The advisory committee subsequently recommended inclusion, and the October 2026 HHS interim policy covers Semax free base for intranasal use only, subject to its conditions. These include a patient-specific prescription, specified ingredient-quality controls, reporting requirements and a single active ingredient. It does not cover Semax acetate, injections or Selank-Semax blends.[12]

The Federal Register calls the policy a draft and describes it as interim and nonbinding. It is not drug approval or a final addition to the 503A bulks list. This status was checked on November 9, 2026.[13]

The evidence at a glance

Stroke recovery

Small studies report selected functional benefits alongside usual care, with important design limitations.

Healthy volunteers

A small task experiment found benefits; separate brain-imaging results measure a different outcome.

Other diseases

A motor-neuron study did not show slower progression. Alzheimer findings discussed here are in mice.

Product and route

Nasal research and conditional US compounding policy do not establish injectable safety or benefit.

What would make the discussion useful?

The outcome

  • Are we discussing recovery after a diagnosed injury, or everyday concentration?
  • Did the study measure a change that matters for that goal?

The evidence

  • Was Semax added to rehabilitation or other treatment?
  • How well did the comparison account for expectations, timing and natural recovery?

The clinical plan

  • What exact product and route are proposed, and what local requirements apply?
  • How will seizure history, psychiatric symptoms, other medicines and adverse effects be assessed?

What to take away

Semax has human research, including some encouraging functional and cognitive findings. The studies leave substantial uncertainty about reproducible benefit, long-term safety and use outside the preparations and settings tested. A useful conversation starts with the exact health problem and the outcome someone hopes to change.

Questions people ask

Does Semax improve recovery after stroke?

Small studies have reported selected benefits when Semax was added to usual care or rehabilitation. The 2018 study found better activities-of-daily-living scores but no clear Semax-related improvement in limb weakness. Design limitations and rehabilitation timing make the size and reliability of benefit uncertain.

Has Semax been studied for focus in healthy people?

Yes. A small 1996 double-blind experiment in 16 male operators reported better performance on several attention and short-term-memory measures, alongside an unexplained increase in spontaneous false responses. Later imaging studies found brain-network changes. These findings do not establish reliable everyday cognitive enhancement.

Are nasal Semax and injectable Semax interchangeable?

No evidence reviewed here establishes that. Russian products and the human studies discussed here use nasal preparations. FDA found no safety data for the proposed subcutaneous route in its 2026 evaluation. Formulation, concentration, delivery and product quality all matter.

Is Semax FDA-approved under the new peptide policy?

No. As checked November 9, 2026, the HHS interim policy concerns conditional compounding of Semax free base for intranasal use with a single active ingredient. It does not include Semax acetate, injections or Selank-Semax blends. The policy is not FDA drug approval or a final 503A bulks-list rule.

The evidence

Sources used for this article. Labels distinguish original clinical studies, laboratory findings, product instructions and regulatory information.

Mouse Alzheimer disease model, 2025The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease PubMed 41479572
Randomized rehabilitation subgroups, 110 patientsThe efficacy of semax in the treatment of patients at different stages of ischemic stroke PubMed 29798983
Rat gene-expression experimentThe peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis PubMed 24661604
Comparative stroke study, 1997Effectiveness of Semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study) PubMed 11517472
Rat gene-expression experiment, 2024ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke PubMed 39767736
Small randomized healthy-volunteer experimentKaplan et al. Synthetic ACTH analogue Semax displays nootropic-like activity in humans. Neuroscience Research Communications. 1996;19:115-123. Author-hosted original paper
Placebo comparison, brain imagingEffects of Semax on the Default Mode Network of the Brain PubMed 30225715
Open-label motor-neuron-disease studyThe study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax PubMed 18379501
Russian product instructions, 1%Semax 1% nasal drops: medical-use instructions. 1% product instructions
Russian product instructions, 0.1%Semax 0.1% nasal drops: medical-use instructions. 0.1% product instructions
FDA staff evaluation, July 2026Semax (free base) and Semax acetate: Pharmacy Compounding Advisory Committee briefing. FDA briefing
HHS interim policyEnforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendices A and B. HHS policy
Federal Register notice, October 2026Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice
Preprint, clinical-note review, 2026Increasing Direct-to-Consumer Use of Semax and Selank Peptides Decoded from LLM-Curated Clinical Notes and Physician Adjudication. Original preprint

Sources checked November 9, 2026. This focused review uses original Russian reports and product instructions where accessible, alongside indexed abstracts and current US regulatory sources. Translation, access limits and publication-notice searches are recorded in the source review.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Semax is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.